trapidil has been researched along with Bone Loss, Osteoclastic in 1 studies
Trapidil: A coronary vasodilator agent.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, SD | 1 |
| Kim, HN | 1 |
| Lee, JH | 1 |
| Jin, WJ | 1 |
| Hwang, SJ | 1 |
| Kim, HH | 1 |
| Ha, H | 1 |
| Lee, ZH | 1 |
1 other study available for trapidil and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Marrow Cells; Bone Resorption; Calci | 2013 |